Finding small molecules that target a specific protein involved in leukemia
Discovery of small molecules targeting the histone acetylation reader ENL
This study is looking for new ways to create small medicines that can block a protein called ENL, which is important in certain types of leukemia, especially those linked to changes in the MLL gene, with the hope of finding better treatments for patients with these aggressive cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Van Andel Research Institute NIH-funded |
| Lab location | 1 site (Grand Rapids, United States) |
| Project ID | NIH-10747882 on NIH RePORTER |
What this research studies
This research focuses on developing small molecules that can inhibit the ENL protein, which plays a crucial role in certain types of leukemia, particularly those associated with MLL gene rearrangements. By targeting ENL, the research aims to disrupt the pathways that lead to the development of these aggressive cancers. The approach involves understanding the molecular mechanisms of ENL and its interactions within the super elongation complex, which is vital for the oncogenic function of MLL fusions. Patients may benefit from new therapeutic options that could improve outcomes for those with these specific leukemia subtypes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with infant acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) associated with MLL gene rearrangements.
Not a fit: Patients with leukemia types not associated with MLL gene rearrangements may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for patients with aggressive forms of leukemia.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in leukemia, indicating potential for success in this novel approach.
Where this research is happening
Grand Rapids, United States
- Van Andel Research Institute — Grand Rapids, United States (Active)
Researchers
- Principal investigator: Wen, Hong — Van Andel Research Institute
- Study coordinator: Wen, Hong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.